Skip to content

BillionToOne, Inc. BLLN Issuances of common stock from employee benefit plans receivable

Issuances of common stock from employee benefit plans receivable at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$108.4M+83.8%
Gross profit$79.1M+108%
Operating income$17.8M+870%
Net income$18.0M+551%
EPS (diluted)$0.34+187%

Balance sheet

See full
Cash & equivalents$537.5M+181%
Total debt$144.2M
Total equity$505.6M+300%
Total assets$700.7M

Cash flow

See full
Operating cash flow$15.4M+488%
CapEx$4.5M+90.5%
Free cash flow$11.0M+3,842%

Valuation

See full
Market cap$4.84B
Enterprise value$4.44B
P/E163.1×
P/S13.6×

Profitability

See full
Gross margin70.4%
Operating margin-96.9%
Net margin8.4%
FCF margin-83.4%

Returns & leverage

See full
Return on equity23.5%
Debt / equity0.3×
Current ratio10.9×

Where this comes from

Reported directly by BillionToOne, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ConversionOfStockAmountIssued1.

The official record: BillionToOne, Inc. ’s 10-K, filed March 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about BillionToOne, Inc. 's issuances of common stock from employee benefit plans receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BillionToOne, Inc. 's issuances of common stock from employee benefit plans receivable?
BillionToOne, Inc. (BLLN) reported issuances of common stock from employee benefit plans receivable of $104.85M in Q4 2025.
What does issuances of common stock from employee benefit plans receivable mean?
Represents the value of common stock issued to employees or directors through equity-based compensation plans. This metric tracks the non-cash issuance of shares that serves as a component of total employee remuneration. It provides insight into the company's reliance on equity incentives to attract and retain talent.